Global GM1 Gangliosidosis Treatment Market Reaches USD 194.2 Mn in 2026, Driven by Advancements in Gene Therapy and Increasing Rare-Disease Research

Innovations in Gene Replacement Therapies and Expanding Clinical Development Pipelines to Drive Global GM1 Gangliosidosis Treatment Market to USD 1,658.9 Mn by 2033 at 36.7% CAGR – Coherent Market Insights

Global GM1 Gangliosidosis Treatment Market, by Product Type (LYS-GM101, PBGM01, AXO-AAV-GM1), by Disease Type (Type 1 GM1 Gangliosidosis, Type 2 GM1 Gangliosidosis, and Type 3 GM1 Gangliosidosis), and by Region (North America,  Europe and Rest of World) is estimated to be valued at US$ 194.2 Mn in 2026 and is expected to exhibit a CAGR of 36.7% during the forecast period, as highlighted in a new report published by Coherent Market Insights.

The global GM1 gangliosidosis treatment market is expected to witness significant growth owing to increasing investment in research and development of disease-modifying therapies, particularly adeno-associated virus-based gene replacement treatments. For instance, in March 2026, UMass Chan Medical School reported results from a Phase 1/2 trial evaluating a single intravenous infusion of AAV9-based gene therapy in nine patients with Type II GM1 gangliosidosis. The study demonstrated improvements in disease biomarkers and neuroimaging patterns, while some participants experienced stable or improved rates of developmental deterioration over a three-year follow-up period. These findings support the continued clinical development of gene therapies targeting the underlying GLB1 enzyme deficiency.

Moreover, biopharmaceutical companies are advancing brain-penetrant small-molecule therapies into late-stage clinical development. In February 2026, Azafaros confirmed that nizubaglustat, an investigational oral therapy with a dual mechanism targeting abnormal lipid accumulation, was being evaluated in ongoing Phase 3 registrational studies for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C. The GM1/GM2 subprotocol is an 18-month, randomized, double-blind and placebo-controlled Phase 3 study evaluating the treatment in patients with late-infantile and juvenile-onset disease. Such late-stage clinical programs are expected to strengthen the GM1 gangliosidosis treatment pipeline, particularly as no disease-modifying treatment is currently available.

To know the latest trends and insights prevalent in the Global GM1 Gangliosidosis Treatment market, click the link below:

https://www.coherentmarketinsights.com/market-insight/gm1-gangliosidosis-treatment-market-4270

The global GM1 gangliosidosis treatment market is expected to witness significant growth as biotechnology companies increasingly collaborate with clinical investigators, healthcare institutions, patient associations, and rare-disease experts to accelerate therapy development and broaden clinical-trial access. For instance, in January 2026, Azafaros announced that its global Phase 3 program evaluating nizubaglustat for GM1 and GM2 gangliosidoses was recruiting patients through multiple clinical sites across the U.S., India, and key European countries. The company stated that it was advancing the studies in collaboration with the global medical community and patient associations. These partnerships support patient recruitment, natural-history data collection, regulatory engagement, and multicountry clinical development, thereby strengthening the treatment pipeline and expanding the geographical presence of investigational therapies for GM1 gangliosidosis.

Global GM1 Gangliosidosis Treatment Market Trends

• Movement toward late-stage, disease-modifying oral therapies: The treatment pipeline is expanding beyond supportive care toward therapies designed to slow neurological disease progression. In January 2026, Azafaros confirmed that its oral, brain-penetrant candidate nizubaglustat was recruiting patients in a global Phase III program for late-infantile and juvenile GM1 and GM2 gangliosidoses. The candidate uses a dual mechanism intended to reduce abnormal glycosphingolipid accumulation and improve lysosomal function. (Source: Azafaros)
• Growing clinical validation of AAV-based gene replacement therapy: Gene therapy remains a major development trend because GM1 gangliosidosis is caused by deficient beta-galactosidase resulting from GLB1 mutations. In March 2026, UMass Chan Medical School reported that a Phase I/II trial involving a single intravenous AAV gene-vector infusion produced improved biomarkers and neuroimaging patterns. Some patients also experienced stable or improved rates of developmental deterioration, with neuronal-fibre gains observed up to three years after treatment. (Source: UMass Chan Medical School)
• Shift toward treatment before irreversible neurological damage: Developers are increasingly evaluating intervention at much earlier disease stages. A Phase I study registered in 2026 is investigating prenatal intravenous administration of an AAV9 vector expressing human beta-galactosidase in fetuses diagnosed with Type I or Type II GM1 gangliosidosis. This represents an emerging move toward in-utero treatment before substantial ganglioside accumulation and neurodegeneration occur. (Source: ClinicalTrials)
• Greater use of natural-history data and quantitative neurological endpoints: Small patient populations and variable disease progression make conventional trial design difficult. The PRONTO prospective study is tracking neurological progression in GM1 and GM2 patients, while 24-month natural-history findings were presented at WORLDSymposium 2026. Developers are also using developmental scales, biomarkers and advanced diffusion-tensor MRI to quantify treatment effects more precisely. (Source: ClinicalTrial.gov)
• Expansion of multinational clinical-trial networks: GM1 treatment studies are becoming increasingly global to overcome limited patient availability. In 2026, nizubaglustat Phase III recruitment included clinical sites across the European Union, India and the U.S., supported through collaboration with healthcare professionals, clinical investigators and patient associations. This approach is improving patient identification, recruitment and geographical access to investigational treatment.
• Increasing regulatory support for rare-disease candidates: Developers are using orphan-drug, rare-pediatric-disease and expedited-development pathways to advance GM1 therapies. Nizubaglustat has received FDA Orphan Drug, Rare Pediatric Disease and Fast Track designations, alongside EMA orphan-medicinal-product status and an MHRA Innovation Passport. However, the FDA database continues to classify the candidate as not approved for the GM1 orphan indication, showing that the market remained predominantly clinical-pipeline driven as of July 2026. (Source: USFDA)
• Development of therapies across multiple related lysosomal disorders: Companies are increasingly designing candidates and master-protocol trials covering GM1, GM2 gangliosidoses and Niemann-Pick disease type C. This platform-based strategy can share clinical infrastructure, neurological endpoints and scientific knowledge across ultra-rare patient populations, potentially improving development efficiency and commercial viability. (Source: curegm1.org)

Key Takeaways of the Global GM1 Gangliosidosis Treatment Market

• The global GM1 gangliosidosis treatment market is expected to exhibit a CAGR of 36.7% during the forecast period owing to an increasing number of ongoing clinical trials for treatment of GM1 gangliosidosis.
• LYS-GM101 segment is estimated to hold major market share in the global Gangliosidosis treatment market, owing to greater efficiency in treatment of GM1 Gangliosidosis rare disorder with recombinant adeno- associated virus 9aav, which directly acts on the nerve cells of the patients.
• Among disease type, Type-1 GM1 gangliosidosis segment is estimated to hold major market share in the global gangliosidosis treatment market owing to rising prevalence of type-1 GM1 gangliosidosis in newborns.
• Key players operating in the global GM1 gangliosidosis treatment market are Lysogene, Axovant Gene Therapies Ltd. and Passage Bio.

Key News

• In June 2026, Azafaros announced that it would present its GM1 gangliosidosis treatment progress at the BIO International Convention in San Diego. The presentation highlighted nizubaglustat, an oral, brain-penetrant investigational therapy with a dual mechanism of action. The candidate is being evaluated in the Phase 3 NAVIGATE program for GM1 and GM2 gangliosidoses, with topline study results expected in 2028, supporting continued late-stage development and future regulatory engagement with authorities. (Source: Azafaros)
• In January 2026, the Cure GM1 Foundation announced plans to invest approximately USD 1.4 million in advancing enzyme replacement therapy for GM1 gangliosidosis, marking its largest commitment to a single research project. The funding will support development activities aimed at progressing the therapy toward an investigational new drug application. The foundation also plans fundraising, sponsorship, and partnership initiatives to de-risk the program and attract long-term grants and future strategic investment. (Source: Cure GM1 Foundation)